Vanguard Group’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$129M Buy
5,405,964
+164,160
+3% +$3.92M ﹤0.01% 1721
2025
Q1
$130M Sell
5,241,804
-22,115
-0.4% -$550K ﹤0.01% 1678
2024
Q4
$99.2M Sell
5,263,919
-34,764
-0.7% -$655K ﹤0.01% 1872
2024
Q3
$79.7M Buy
5,298,683
+213,852
+4% +$3.22M ﹤0.01% 1983
2024
Q2
$145M Sell
5,084,831
-28,553
-0.6% -$817K ﹤0.01% 1663
2024
Q1
$149M Buy
5,113,384
+14,960
+0.3% +$437K ﹤0.01% 1669
2023
Q4
$172M Buy
5,098,424
+141,719
+3% +$4.78M ﹤0.01% 1592
2023
Q3
$152M Buy
4,956,705
+4,393
+0.1% +$135K ﹤0.01% 1575
2023
Q2
$198M Sell
4,952,312
-25,906
-0.5% -$1.04M ﹤0.01% 1479
2023
Q1
$203M Buy
4,978,218
+53,023
+1% +$2.16M 0.01% 1449
2022
Q4
$190M Buy
4,925,195
+56,750
+1% +$2.19M 0.01% 1465
2022
Q3
$259M Buy
4,868,445
+55,188
+1% +$2.94M 0.01% 1232
2022
Q2
$281M Buy
4,813,257
+125,138
+3% +$7.3M 0.01% 1219
2022
Q1
$358M Buy
4,688,119
+22,164
+0.5% +$1.69M 0.01% 1180
2021
Q4
$281M Sell
4,665,955
-102,108
-2% -$6.14M 0.01% 1396
2021
Q3
$267M Buy
4,768,063
+43,134
+0.9% +$2.42M 0.01% 1414
2021
Q2
$287M Buy
4,724,929
+218,398
+5% +$13.3M 0.01% 1396
2021
Q1
$316M Buy
4,506,531
+139,265
+3% +$9.76M 0.01% 1274
2020
Q4
$261M Buy
4,367,266
+78,823
+2% +$4.72M 0.01% 1304
2020
Q3
$258M Sell
4,288,443
-87,536
-2% -$5.26M 0.01% 1108
2020
Q2
$230M Buy
4,375,979
+9,160
+0.2% +$481K 0.01% 1188
2020
Q1
$146M Buy
4,366,819
+22,265
+0.5% +$747K 0.01% 1316
2019
Q4
$197M Sell
4,344,554
-87,274
-2% -$3.95M 0.01% 1397
2019
Q3
$169M Buy
4,431,828
+502,417
+13% +$19.1M 0.01% 1436
2019
Q2
$171M Buy
3,929,411
+7,946
+0.2% +$346K 0.01% 1456
2019
Q1
$149M Buy
3,921,465
+136,320
+4% +$5.19M 0.01% 1524
2018
Q4
$163M Buy
3,785,145
+143,728
+4% +$6.18M 0.01% 1377
2018
Q3
$179M Buy
3,641,417
+243,213
+7% +$12M 0.01% 1467
2018
Q2
$109M Buy
3,398,204
+114,756
+3% +$3.68M ﹤0.01% 1733
2018
Q1
$102M Buy
3,283,448
+29,947
+0.9% +$933K ﹤0.01% 1700
2017
Q4
$149M Buy
3,253,501
+85,584
+3% +$3.91M 0.01% 1485
2017
Q3
$119M Buy
3,167,917
+95,843
+3% +$3.6M 0.01% 1609
2017
Q2
$147M Buy
3,072,074
+211,982
+7% +$10.1M 0.01% 1443
2017
Q1
$130M Buy
2,860,092
+112,853
+4% +$5.15M 0.01% 1504
2016
Q4
$88.7M Buy
2,747,239
+80,028
+3% +$2.58M ﹤0.01% 1700
2016
Q3
$91.3M Buy
2,667,211
+79,990
+3% +$2.74M 0.01% 1616
2016
Q2
$87.3M Buy
2,587,221
+64,898
+3% +$2.19M 0.01% 1605
2016
Q1
$134M Buy
2,522,323
+53,485
+2% +$2.83M 0.01% 1276
2015
Q4
$190M Buy
2,468,838
+73,068
+3% +$5.61M 0.01% 1045
2015
Q3
$98.5M Buy
2,395,770
+73,175
+3% +$3.01M 0.01% 1440
2015
Q2
$164M Buy
2,322,595
+82,059
+4% +$5.8M 0.01% 1193
2015
Q1
$199M Buy
2,240,536
+114,403
+5% +$10.2M 0.01% 1047
2014
Q4
$189M Buy
2,126,133
+31,205
+1% +$2.77M 0.01% 1013
2014
Q3
$203M Buy
2,094,928
+14,813
+0.7% +$1.44M 0.02% 917
2014
Q2
$191M Buy
2,080,115
+123,838
+6% +$11.4M 0.02% 988
2014
Q1
$137M Buy
1,956,277
+155,459
+9% +$10.9M 0.01% 1156
2013
Q4
$104M Buy
1,800,818
+503,302
+39% +$28.9M 0.01% 1294
2013
Q3
$62.4M Buy
1,297,516
+530,896
+69% +$25.5M 0.01% 1568
2013
Q2
$22.2M Buy
+766,620
New +$22.2M ﹤0.01% 2040